Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GlucoTrack, Inc. - Common Stock (NQ:GCTK)

0.1600 +0.0030 (+1.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GlucoTrack, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes Management
Via TheNewswire.com
Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes Management
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions
From Glucotrack, Inc.
Via GlobeNewswire
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Upcoming Benzinga Webinar With Glucotrack To Discuss The Potential Of Its Innovative CBGM Technology To Transform Diabetes Care And Patient Lives
Via TheNewswire.com
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology 
From Glucotrack, Inc.
Via GlobeNewswire
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology 
From Glucotrack, Inc.
Via GlobeNewswire
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes Patients
Via TheNewswire.com
First-In-Human Study In The Bag, Glucotrack Gears Up For Long-Term Trial Of Potentially Groundbreaking Continuous Blood Glucose Monitor For Diabetes Patients
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
Long-term clinical evaluation represents key advancement following successful first-in-human study 
From Glucotrack, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Top movers in Monday's after hours session
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Get insights into the top gainers and losers of Wednesday's after-hours session.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
These stocks that are showing activity before the opening bell on Wednesday.
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
Continuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes study 
From Glucotrack, Inc.
Via GlobeNewswire
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data 
From Glucotrack, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Wondering what's happening in today's after-hours session?
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week
Investors reacted to insider buying, clinical trial updates, and strategic business shifts that happened in the week ended March 21, 2025. 
Via Stocktwits
Top stock movements in today's session.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.